Lyxumia hits primary endpoint in Phase 2 trial


Sanofi's (SNY -0.5%) Lyxumia (lixisenatide) met its primary endpoint in an eight-week pharmacodynamic study of a significantly more pronounced lowering of post-prandial glucose after a test meal compared to liraglutide when both were added to optimally-titrated Lantus (insulin glargine). The lowering of post-prandial glucose was measured as the change from baseline in incremental area under the glucose curve for 4 hours after a standardized solid breakfast at week eight.

Lyxumia is currently approved for sale in over 40 countries (ex. U.S.) for the treatment of type 2 diabetes. The company expects to resubmit its NDA in the U.S. in 2015. It withdrew the original NDA in 2013 after discussions with the FDA over interim data in an ongoing cardiovascular outcomes study. The company felt that the public disclosure of the data could potentially compromise the integrity of the study.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs